Heidelberg Pharma AG

Capital/Financing Update • Mar 23, 2010

News Details

Corporate | 23 March 2010 08:04

WILEX AG secures financing up to EUR 20 million through an equity line

WILEX AG / Corporate Action

23.03.2010 08:04

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Munich, 23 March 2010. The biopharmaceutical company WILEX AG (ISIN
DE0006614720/ Frankfurt Stock Exchange / Prime Standard) has entered into
Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV LTD,
(YA Global), a fund managed by Yorkville Advisors, LLC both located in New
Jersey, USA.

The SEDA, an increasingly common instrument in the biotech industry,
entitles WILEX to issue new shares from authorised capital to be sold in
tranches of up to EUR 1 million to YA Global. Upon WILEX' absolute
discretion YA Global is obliged to subscribe for and to purchase such
shares. WILEX intends to propose approval of new authorised capital at the
Annual General Meeting on 21 May 2010. If approved, this would enable the
company to initiate drawing funds starting in June 2010 onwards.

The total value of this equity facility aggregates to up to EUR 20 million,
provided that in no event shall the total number of shares owned by YA
Global exceed 9.9% of WILEX' share capital at any one time. The agreement
is valid for a period of 36 months following contract signature.

Peter Llewellyn-Davies, CFO of WILEX AG noted, 'As our product pipeline
progresses towards commercialization, a strengthened financial position
increases our strategic options. The flexibility afforded by this
additional source of financing will give us the option to raise funds over
a period of three years at our discretion.'

Dr. Michael J. Nowak, Head of the Healthcare Group and a Managing Director
at Yorkville Advisors, LLC, commented: 'Yorkville provides innovative
financing tools for public technology companies. WILEX is one of few
biotechnology companies with two Phase III product candidates, a Phase II
programme and several promising new projects. The company specialises in
oncology and targets indications for which there are currently no approved
products. We are delighted to support WILEX in its transition from a drug
developing company into a commercially driven biopharmaceutical
organisation.'

Contact
WILEX AG
Katja Arnold (CIRO)
Corporate Communications
Grillparzerstr. 10
81675 Munich
Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors@wilex.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Tel.: +49 (0)89-210 228 0
E-mail: raimund.gabriel@mc-services.eu

About WILEX AG

WILEX AG is a biopharmaceutical company based in Munich and is listed at
the Frankfurt Stock Exchange at the Regulated Market / Prime Standard.
WILEX's mission is to develop drugs with a low side effect profile and
targeted treatment of different types of cancer as well as diagnostic
agents for specific detection of tumours. The Company's product candidates
are based on antibodies and small molecules. WILEX has an attractive
product pipeline which includes both drug and diagnostic candidates: The
candidates REDECTANE(R) and RENCAREX(R) are undergoing Phase III
registration trials. MESUPRON(R) is in Phase II trials in two indications.
The MEK inhibitor WX-554 is in a Phase I trial, and the other four oncology
projects (PI3K inhibitor WX-037 and three antibody programmes) are in
preclinical development. WILEX aims within a few years to be able to
finance its research and development programmes from its operating cash
flow.

Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

23.03.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---